| 贝伐珠单抗治疗复发性卵巢癌的应用进展 |
| |
| 引用本文： | 王营,郭志,倪虹. 贝伐珠单抗治疗复发性卵巢癌的应用进展[J]. 肿瘤防治研究, 2015, 42(4): 416-420. DOI: 10.3971/j.issn.1000-8578.2015.04.022 |
| |
| 作者姓名： | 王营 郭志 倪虹 |
| |
| 作者单位： | 300060 天津，天津医科大学肿瘤医院介入治疗肿瘤科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室 |
| |
| 摘 要： | 贝伐珠单抗（Bevacizumab, BEV）是一种重组人源化抗血管内皮生长因子（vascularendothelial growth factor, VEGF）的单克隆抗体，通过阻断VEGF与其受体结合，抑制肿瘤新生血管形成，从而抑制肿瘤生长。临床研究表明，BEV单药治疗复发性卵巢癌的疗效确切，并且与紫杉类药物、脂质体阿霉素及环磷酰胺等药物联合使用疗效更佳。此外，BEV能有效控制恶性腹水，提高患者的生活质量。因此BEV在复发性卵巢癌的治疗中具有广阔的应用前景。
|
| 关 键 词： | 贝伐珠单抗 血管内皮生长因子 复发性卵巢癌 恶性腹水 |
| 收稿时间： | 2014-05-19 |
Bevacizumab in Treatment of Recurrent Ovarian Cancer |
| |
| WANG Ying,GUO Zhi,NI Hong. Bevacizumab in Treatment of Recurrent Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(4): 416-420. DOI: 10.3971/j.issn.1000-8578.2015.04.022 |
| |
| Authors: | WANG Ying GUO Zhi NI Hong |
| |
| Affiliation: | Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laborary of Cancer Prevention and Therapy, Tianjin 300060, China |
| |
| Abstract: | Bevacizumab(BEV), a recombinant humanized anti-VEGF monoclonal antibody, represses the tumor angiogenesis by blocking the binding of VEGF to its receptors，thus to inhibit the growth of malignancies. Clinical studies have demonstrated that BEV is active as a single agent for recurrent ovarian cancer, and exhibits better efficacy when combines with cytotoxic drugs, such as taxane, pegylated liposomal doxorubicin, cyclophosphamide and so on. Moreover, BEV plays an important role in the management of malignant ascites caused by ovarian cancer and significantly improves the patients’ quality of life. Therefore,BEV has broad prospects in the treatment of recurrent ovarian cancer. |
| |
| Keywords: | Bevacizumab(BEV),Vascular endothelial growth factor(VEGF),Recurrent ovarian cancer Malignant ascites, |
|
| 点击此处可从《肿瘤防治研究》浏览原始摘要信息 |
|
点击此处可从《肿瘤防治研究》下载全文 |
|
